In June 2021, when the OlympiA study showed a role for adjuvant olaparib for patients with high-risk Stage 2–3 BC and a germline PV in BRCA1 or BRCA2,[7], the NCCN Guidelines® endorsed germline testing for any females with a new diagnosis of nonmetastatic BC who would be candidates for adjuvant PARP inhibitor therapy [26]. The gene discussed is BRCA2; the disease is breast cancer.